Iparomlimab and Tuvonralimab Injection in Combination With Lenvatinib or Axitinib for the Treatment of Locally Advanced or Metastatic Clear Cell Renal Cell Carcinoma That Has Failed First-Line Systemic Therapy

The primary objective is to evaluate the improvement in Objective Response Rate (ORR) achieved with Iparomlimab and Tuvonralimab Injection (QL1706, an Anti-PD-1/CTLA-4 Combined Antibody) in combination with Lenvatinib or Axitinib, in patients with locally advanced or metastatic clear cell renal cell carcinoma (ccRCC) who have failed first-line systemic therapy.

NCT Number	NCT07277972
Lead Sponsor	Tianjin Medical University Cancer Institute and Hospital
Conditions	RCC, Renal Cell Cancer
Enrollment	36 participants
Start Date	2026-02-15
Primary Completion	2029-11-30 (estimated)
Study Completion	2031-08-31 (estimated)
Updated on ClinicalTrials.gov	2025-12-11